Issuance of Series 14 Stock Acquisition Rights through a Third-Party Allotment and Fundraising for New Product Development
First written in FY2022-Q3. 15 of 16 entries say "Advanced", first in FY2022. Latest entry: FY2026.
20 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Following the end of the consolidated fiscal year, all of the Series 18 subscription rights issued by the company on 14 April 2025, with an exercise-price adjustment clause, were exercised.」
During the period, the Series 18 subscription rights resulted in the delivery of 28,800,000 shares and fundraising of ¥1,425 million. The exercise of the remaining 3,200,000 shares was also completed by 24 June 2026, after the financial results were announced. - FY2026-H1AdvancedAnnual report
「Number of the exercise-price adjustment clause subscription rights exercised during the interim accounting period (units) 235,700 Number of shares delivered upon exercise during the interim accounting period (shares) 23,570,000 Funds raised through exercises during the period (¥ millions) 1,181」
During the first half, 235,700 Series 18 subscription rights were exercised, 23,570,000 shares were delivered and ¥1,181 million was raised. Fundraising for new product development and working capital made significant progress. - FY2025AdvancedAnnual report
「The Series 14 share acquisition rights issued by the company on 14 February 2022 and the Series 15 share acquisition rights issued on 13 May 2022 were exercised. As a result, during the first half of the current consolidated fiscal year, capital stock and capital surplus each increased by ¥525.553 million, and at the end of the first half of the current consolidated fiscal year, capital stock was ¥2,214.325 million and capital surplus was ¥648.666 million.」
During the period, 4,000,000 shares were delivered upon the exercise of Series 17 subscription rights and ¥341 million was raised, bringing cumulative funds raised to ¥677 million. Following the issuance of Series 18 subscription rights, the exercise of 12,838,500 shares was recorded in the subsequent period. - FY2025-H1AdvancedAnnual report
「Number of the exercise-price adjustment clause subscription rights exercised during the interim accounting period (units) 40,000 Number of shares delivered upon exercise during the interim accounting period (shares) 4,000,000 Funds raised through exercises during the period (¥ millions) 341 Cumulative funds raised through the exercise-price adjustment clause subscription rights as of the end of the interim accounting period (¥ millions) 677」
During the first half, 4,000,000 shares were delivered upon the exercise of Series 17 subscription rights and ¥341 million was raised. Cumulative totals were 8,000,000 shares and ¥677 million, indicating progress in fundraising for new product development and other purposes. - FY2024-Q3AdvancedAnnual report
「Number of the exercise-price adjustment clause subscription rights exercised during the period (units) 24,500 Number of shares delivered upon exercise during the period (shares) 2,450,000 Funds raised through exercises during the period (¥ millions) 100 Cumulative number of exercise-price adjustment clause subscription rights exercised as of the end of the period (units) 104,670 Cumulative number of shares delivered upon exercise of the exercise-price adjustment clause subscription rights as of the end of the period (shares) 10,467,000 Cumulative funds raised through the exercise-price adjustment clause subscription rights as of the end of the period (¥ millions) 475」
During the third quarter, 24,500 Series 16 subscription rights were exercised, 2.45 million shares were delivered and ¥100 million was raised. Cumulatively, 10,467,000 shares had been delivered and ¥475 million had been raised. - FY2024-Q2AdvancedAnnual report
「Number of the exercise-price adjustment clause subscription rights exercised during the period (units) 40,170 Number of shares delivered upon exercise during the period (shares) 4,017,000 Funds raised through exercises during the period (¥ millions) 167」
During the second quarter, 40,170 Series 16 subscription rights were exercised, 4,017,000 shares were delivered and ¥167 million was raised. Cumulatively, the totals were 80,170 rights, 8,017,000 shares and ¥375 million. - FY2024-Q1AdvancedAnnual report
「Number of the exercise-price adjustment clause subscription rights exercised during the period (units) 30,000 Number of shares delivered upon exercise during the period (shares) 3,000,000 Funds raised through exercises during the period (¥ millions) 149」
During the quarter, 30,000 Series 16 subscription rights were exercised, 3,000,000 shares were delivered and ¥149 million was raised. The company further implemented its capital policy for new product development and other purposes. - FY2023AdvancedAnnual report
「At a meeting of the Board of Directors held on 7 March 2023, the company resolved to issue Series 16 and Series 17 share acquisition rights to be allotted to EVO FUND, and issued them on 23 March 2023.」
The company issued Series 16 and Series 17 share acquisition rights, and 1 million shares were issued upon exercise of the Series 16 rights during the current fiscal year. Proceeds from the issuance of shares amounted to ¥1,136.774 million, and funding for new product development and other purposes advanced through the execution stage. - FY2023-Q3AdvancedAnnual report
「The Series 14 share acquisition rights issued by the company on 14 February 2022 and the Series 15 share acquisition rights issued on 13 May 2022 were exercised. As a result, during the first nine months of the current consolidated fiscal year, capital stock and capital surplus each increased by ¥540.556 million, and at the end of the third quarter of the current consolidated fiscal year, capital stock was ¥2,229.328 million and capital surplus was ¥663.669 million.」
The Series 14 and Series 15 share acquisition rights continued to be exercised, increasing capital stock and capital surplus by ¥540.556 million each during the first nine months. The capital policy for new product development and other purposes advanced further to the execution stage. - FY2023-Q2AdvancedAnnual report
「The Series 14 share acquisition rights issued by the company on 14 February 2022 and the Series 15 share acquisition rights issued on 13 May 2022 were exercised. As a result, during the first half of the current consolidated fiscal year, capital stock and capital surplus each increased by ¥525.553 million, and at the end of the first half of the current consolidated fiscal year, capital stock was ¥2,214.325 million and capital surplus was ¥648.666 million.」
The Series 14 and Series 15 share acquisition rights continued to be exercised, increasing capital stock and capital surplus by ¥525.553 million each during the first half. The capital policy for new product development and other purposes advanced further to the execution stage. - FY2023-Q1AdvancedAnnual report
「The Series 14 share acquisition rights issued by the company on 14 February 2022 and the Series 15 share acquisition rights issued on 13 May 2022 were exercised. As a result, during the first quarter of the current consolidated fiscal year, capital stock and capital surplus each increased by ¥277.004 million, and at the end of the first quarter of the current consolidated fiscal year, capital stock was ¥1,965.775 million and capital surplus was ¥400.116 million.」
The Series 14 and Series 15 share acquisition rights were exercised, increasing capital stock and capital surplus by ¥277.004 million each during the quarter. Funding under the company’s capital policy advanced to the execution stage. - FY2022AdvancedAnnual report
「At a meeting of the Board of Directors held on 8 April 2022, the company resolved to issue Series 15 share acquisition rights. The issuance was approved at the company’s extraordinary general meeting of shareholders held on 12 May 2022, and the share acquisition rights were issued on 13 May 2022.」
During the current fiscal year, 740 Series 14 share acquisition rights, equivalent to 74,000 shares, were exercised, and the remaining rights were exercised after the fiscal year-end. In addition, the company issued 156,200 Series 15 share acquisition rights, representing 15,620,000 potential shares, and planned to raise ¥781,156,200 for new product development and working capital. - FY2022-Q3First statedAnnual report
「At a meeting of the Board of Directors held on 27 January 2022, the company resolved to issue Series 14 share acquisition rights with adjustment provisions for the exercise price by way of a third-party allotment to Mita Securities Co., Ltd. as the allottee.」
The company resolved to issue 14,000 share acquisition rights, with 14 February 2022 as the allotment date. The estimated net proceeds if all rights were exercised were ¥328,538,000. The funds were to be used for new product development, and the exercise price was subject to adjustment, with a floor of ¥121.